Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis [version 1; peer review: 1 approved, 2 approved with reservations]

Cahyo Wibisono Nugroho¹,², Satriyo Dwi Suryantoro¹,², Yuliasih Yuliasih¹, Alfian Nur Rosyid²,³, Tri Pudy Asmarawati¹,², Lucky Andrianto²,⁴, Herley Windo Setiawan²,³, Bagus Aulia Mahdi¹, Choirina Windradi¹, Esthiningrum Dewi Agustin⁵, Jonny Karunia Fajar⁶

¹Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60132, Indonesia
²Universitas Airlangga, Surabaya, East Java, 60115, Indonesia
³Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60132, Indonesia
⁴Department of Anesthesiology and Reanimation, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60132, Indonesia
⁵Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60132, Indonesia
⁶Department of Internal Medicine, Faculty of Medicine, Brawijaya University, Malang, East Java, 65145, Indonesia

Abstract

Background: Several studies have revealed the potential use of tocilizumab in treating COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab may provide clinical benefits for cytokine release syndrome in COVID-19 patients.

Methods: We searched for relevant studies in PubMed, Embase, Medline, and Cochrane published from March to October 2020 to evaluate optimal use and baseline criteria for administration of tocilizumab in severe and critically ill COVID-19 patients. Research involving patients with confirmed SARS-CoV-2 infection, treated with tocilizumab and compared with the standard of care (SOC) was included in this study. We conducted a systematic review to find data about the risks and benefits of tocilizumab and outcomes from different baseline criteria for administration of tocilizumab as a treatment for severe and critically ill COVID-19 patients.

Results: A total of 26 studies, consisting of 23 retrospective studies, one prospective study, and two randomised controlled trials with 2112 patients enrolled in the tocilizumab group and 6160 patients in the SOC group, were included in this meta-analysis. Compared to the SOC, tocilizumab showed benefits for all-cause mortality events and a shorter time until death after first intervention but showed no difference in hospital length of stay. Upon subgroup analysis, tocilizumab showed fewer all-cause mortality events when CRP level
≥100 mg/L, P/F ratio 200-300 mmHg, and P/F ratio <200 mmHg. However, tocilizumab showed a longer length of stay when CRP <100 mg/L than the SOC.

**Conclusion:** This meta-analysis demonstrated that tocilizumab has a positive effect on all-cause mortality. It should be cautiously administrated for optimal results and tailored to the patient's eligibility criteria.

**Keywords**
Severe, critically ill, COVID-19, tocilizumab
Introduction

In December 2019, a novel virus named Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) that causes Coronavirus Disease-19 (COVID-19) began to spread worldwide and it become a pandemic globally. COVID-19 manifestation ranges broadly from mild symptoms to severe illness. Several studies probed multiple types of inflammatory cytokine levels and found higher levels of interleukin (IL)-1β, IL-1RA, IL-6, IL-7, IL-8, IL-10, IFN-γ, monocyte chemoattractant peptide-1, macrophage inflammatory protein (MIP)-1A, MIP-1B, granulocyte-colony stimulating factor, and tumor necrosis factor-alpha in severe COVID-19 patients. COVID-19 causes severe illness due to activation of the cytokine cascade leading to cytokine release syndrome (CRS), which is delineated by systemic inflammation and multiple organ failure. Therefore, prompt strategies for treating CRS are essential for COVID-19 patients.

IL-6 is a proinflammatory cytokine that plays an essential role in CRS. Activation and secretion of IL-6 by infected monocytes, macrophages, and dendritic cells cause two main effects; a plethoric effect on immune cells and the innate immune system, and increased vascular permeability due to secretion of vascular endothelial growth factor (VEGF), resulting in hypotension and acute respiratory distress syndrome.

Tocilizumab, a humanized monoclonal antibody interleukin-6 receptor (IL-6R) inhibitor, is recommended by the National Health Commission of China for treating severe and critically ill patients with elevated IL-6. Recently, several case reports demonstrated tocilizumab could improve the clinical manifestations of seriously ill COVID-19 patients. Several retrospective case-control, single-armed studies and randomized clinical trials declared promising results of tocilizumab treatment in SARS-CoV-2 infection. Nevertheless, some systematic reviews and meta-analyses showed an unclear risk of bias and reported debatable results about tocilizumab’s benefit as a treatment.

We performed a systematic review and meta-analysis to research the risks and benefits of tocilizumab and investigate outcomes from different baseline criteria for administration of tocilizumab as a treatment for severe and critically ill COVID-19 patients.

Methods

Study design

We conducted a systematic review and meta-analysis to examine optimal use and baseline criteria for administration of treatment with tocilizumab versus standard of care (SOC) in severe and critically ill COVID-19 patients using data published March to October 2020. All-cause mortality events, length of stay in hospital, and days until death (time to death after first intervention) were measured to determine the risks and benefits of tocilizumab treatment. The baseline criteria for using tocilizumab included physical findings and markers of inflammation such as C-reactive protein (CRP), PaO2 and FiO2 ratio (P/F ratio), lactate dehydrogenase (LDH), D-dimer, ferritin, IL-6, leucocyte, lymphocyte count, platelet count, and procalcitonin. We performed screening of several medical databases (PubMed, Embase, Medline, and Cochrane) to collect data and calculate the risk ratio (RR) and 95% confidence intervals (95% CI). This study used similar methods for the systematic review and meta-analysis to a previous study, and was reported according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines accessed from the PRISMA website.

Literature search

The search strategy, using medical subject headings (MeSH) terms, involved the use of a combination of the following keywords: (tocilizumab) OR (anti-IL-6 monoclonal antibody) OR (IL-6 blockade) OR (IL-6 receptor antagonist) AND severe AND critical ill AND (COVID-19) OR (novel coronavirus disease) OR (SARS-CoV-2). The search was performed by two authors (BAM and CW) in PubMed, Embase, Medline, and Cochrane (March 1st to October 31st 2020, last searched 2nd November 2020) and the language was limited to English. We selected 606 full text and free full text articles from PubMed, included all article types, then we excluded them based on the exclusion criteria of case reports, reviews, editorials, letters, duplicate records, and studies with incomplete data. Filter selection of clinical trials, meta analyses, randomized control trials and systematic reviews within one year we got 42 articles after removing 655 articles (see Figure 1).

Selection criteria

The studies in the three searched databases were included based on the following criteria: (1) patient confirmed for SARS-CoV-2 infection; (2) patients treated with tocilizumab and compared with the SOC; and (3) complete data were provided for clinical outcomes. Exclusion criteria were (1) case reports, reviews, editorials, and letters; (2) duplicate records; and (3) studies with incomplete data.

Data extraction and quality assessment

All articles that qualified for inclusion according to the selection criteria were included in the analysis. Two independent investigators conducted the study assessment (BAM and CW). Two authors (BAM and EA) extracted necessary data from each included study including: first author, publication year, sample size, gender, baseline criteria for administration of tocilizumab, clinical outcomes of tocilizumab group and SOC group. Another consultant resolved any disagreement between the two investigators’ findings (ANR and TPA).

The methodological quality assessment

We performed a methodological quality assessment of the article using the Newcastle-Ottawa Scale (NOS) before study inclusion. NOS comprises several items including: patient selection (4 points), comparability of the groups (2 points), and ascertainment of exposure (3 points). Each study was interpreted to be low quality (scores <4), moderate quality (scores of 5–6), or high quality (scores ≥7). We only included moderate to high quality articles in the analysis. The study assessment was conducted by two independent investigators (CW and EA) using a pilot form. Another consultant resolved any disagreement between the two investigators’ findings (CWN and SDS).

Page 3 of 18
Outcomes
The study outcomes were all-cause mortality events, length of stay in hospital, and days until death (time to death after first intervention), comparing SOC and tocilizumab. We performed subgroup analysis for those outcomes based on CRP level >100 mg/L, CRP level <100 mg/L, PaO₂:FiO₂ ratio (P/F ratio) 200–300 mmHg, and PaO₂:FiO₂ (P/F ratio) <200 mmHg.

Statistical analysis
Data were synthesized using RRs and mean differences (MDs), with 95% CIs. Significance of RRs was determined using the Z test (p<0.05 was considered statistically significant). They were assessed for heterogeneity and possibility of publication bias before calculating significance. We used the Q test for evaluating the heterogeneity among the included studies. A random effect model was used if heterogeneity existed (p<0.10); if not, a fixed-effect model was adopted. For publication bias, we used Egger’s test and a funnel plot (p<0.05 was considered statistically significant).

We analyzed the data with Review Manager (RevMan, Cochrane, London, UK) version 5.4.1. Two authors (BAM and JKF) conducted statistical analysis and presented the results in a forest plot.
Results
Qualifying studies
We obtained 697 qualifying studies, 655 of which were excluded after examining the titles and abstracts. We performed a review of the complete texts for 42 potential studies and 16 studies were then excluded because they were reviews (n=2); systematic review and meta-analyses (n=5); letters (n=1); single-center experiences (n=4); case reports (n=1); brief papers (n=1) or had incomplete data (n=2). Eventually, 26 papers met the inclusion criteria for our meta-analysis; these results are summarized in Figure 1. The characteristics of studies are described in Table 1. We have summarized the results of the outcomes in Table 2.

Outcomes of tocilizumab treatment
There is a significant difference between the SOC group and tocilizumab group (RR: 1.65; 95% CI = 1.37, 2.00) from all-cause mortality events (Figure 2) and days until death (time to death after first intervention) (MD: 6.03; 95% CI: 0.31, 11.76). There is no significant difference between the length of stay (MD: -2.05; 95% CI: -5.25, 1.16). All outcomes showed evidence of heterogeneity and the random effect model was adopted.

Subgroup analysis
There is a significant difference in all-cause mortality events for patients with CRP level >100 mg/L (RR: 1.78; 95% CI: 1.35, 2.34); P/F ratio 200–300 mmHg (RR: 1.84; 95% CI: 1.35, 2.50); and P/F ratio <200 mmHg (RR: 1.44; 95% CI: 1.28, 1.63). For length of stay in hospital, CRP level <100 mg/L showed a significant difference (MD: -7.75; 95% CI: -10.31, -5.20) (Figure 3).

Within the subgroup analysis, evidence of homogeneity was found and we used the fixed effect model for all-cause mortality events for P/F ratio <200 mmHg and length of stay for CRP level ≥100 mg/L, CRP level <100 mg/L, and P/F ratio 200–300 mmHg. The other parameters were analyzed using the random effect model.

Analysis of publication bias
We assessed the possibility of publication bias using Egger’s test. There was no indication of publication bias (p<0.05) for all outcomes.

Discussion
To the best of our knowledge, this is the first meta-analysis investigating the optimal use of tocilizumab in severe and critically ill COVID-19 patients. The 26 studies analysed, mostly retrospective studies with only two clinical trials (Salvarini et al. and Somerset et al.), suggest that treatment with tocilizumab gives fewer all-cause mortality events than the SOC. Lan et al. showed that tocilizumab could not provide additional benefits for clinical outcomes of severe COVID-19, but the mortality rate was lower than the SOC, although this was not statistically different. Studies from Kaye et al., Zhao, J et al., and Zhao, M et al., reported that tocilizumab showed a statistically significant reduction in mortality and fatality than the SOC, similar to our results.

Nevertheless, hospital and ICU lengths of stay did not differ between tocilizumab and SOC. Only one study (Eimer et al.) showed that length of stay in hospital on tocilizumab was shorter than the SOC and it was able to shorten the duration of use of a ventilator. However, for the variable days until death, intervention with tocilizumab resulted in a shorter duration until death than the SOC due to secondary infections after tocilizumab treatment.

Selection criteria from included studies for using tocilizumab treatment for COVID-19 mostly included similar clinical manifestations but baseline laboratory parameters varied. Clinical manifestations for tocilizumab treatment eligibility were frequency of respiration ≥30 breaths/min and peripheral capillary oxygen saturation (SpO2) <93% while breathing ambient air. Laboratory markers for tocilizumab treatment eligibility were P/F ratio, CRP, ferritin, LDH and IL-6. In most studies, baseline criteria for administration of tocilizumab were level of CRP ≥100 mg/L (normal values <6 mg/L), ferritin ≥900 ng/mL (normal value <400 ng/mL), LDH >220 U/L, and P/R ratio ≥200–300 mmHg. However, several studies used baseline criteria for administration of tocilizumab of CRP >100 mg/L and P/F ratio <200 mmHg.

The SMACORE study used baseline criteria for administration of tocilizumab of CRP >50 mg/L, procalcitonin <0.5 ng/mL and P/F ratio <300 mmHg in seriously ill COVID-19 patients. Tocilizumab was first administered at 8 mg/kg (up to a maximum 800 mg per dose) intravenously, repeated after 12 hours if no side effects were reported after the first dose. The result from this study was that tocilizumab administration did not reduce mortality rate or ICU admissions.

Similar selection criteria were used by Masia et al.; the eligible participants had CRP >50 mg/L and tocilizumab was given at an initial dose of 600 mg intravenously for a weight of >75 kg or 400 mg when the weight was <75 kg. If their condition worsened, treatment was reevaluated following 24 hours. A second dose of tocilizumab (400 mg) was given if there was no clinical response. The result from this study was that tocilizumab administration significantly reduced the mortality rate.

In the randomized trial by Salvarini et al., the selection criteria for tocilizumab treatment were P/F ratio of 200–300 mmHg. Tocilizumab was given intravenously at a starting dose of 8mg/kg until 800 mg within eight hours of randomization, and a second dose administered after 12 hours. This study showed no benefit on disease progression in the tocilizumab group compared with the SOC.
<table>
<thead>
<tr>
<th>Article</th>
<th>Study design</th>
<th>Country</th>
<th>Total patients</th>
<th>Mean/median age (years)</th>
<th>TCZ category**</th>
<th>Baseline criteria for TCZ administration</th>
<th>Outcome</th>
<th>NOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albertini 2020</td>
<td>Single-center retrospective observational cohort study</td>
<td>France</td>
<td>44</td>
<td>65 (control) 64 (tocilizumab)</td>
<td>C</td>
<td>CRP ≥ 100mg/L</td>
<td>Clinical and laboratory marker and death</td>
<td>6</td>
</tr>
<tr>
<td>Biran 2020</td>
<td>Retrospective multicentre observational cohort study</td>
<td>USA</td>
<td>764</td>
<td>65 (control) 62 (tocilizumab)</td>
<td>B</td>
<td>CRP ≥ 100 mg/L Ferritin &gt; 900 ng/mL PaO2:FiO2 200-300 mmHg</td>
<td>Hospital-related mortality</td>
<td>8</td>
</tr>
<tr>
<td>Campochiaro 2020</td>
<td>Single-center retrospective cohort study</td>
<td>Italy</td>
<td>65</td>
<td>60 (control) 64 (tocilizumab)</td>
<td>B</td>
<td>CRP ≥ 100 mg/L Ferritin &gt; 900 ng/mL LDH &gt;220 U/L PaO2:FiO2 200-300 mmHg</td>
<td>Safety, efficacy</td>
<td>8</td>
</tr>
<tr>
<td>Canziani 2021</td>
<td>Retrospective case-control study</td>
<td>Italy</td>
<td>128</td>
<td>63 (control) 64 (tocilizumab)</td>
<td>A</td>
<td>CRP &gt;50 mg/L Ferritin &gt;900ng/mL LDH &gt;220 U/L PaO2:FiO2 &lt; 200 mmHg</td>
<td>Death</td>
<td>9</td>
</tr>
<tr>
<td>Capra 2020</td>
<td>Retrospective observational case-control study</td>
<td>Italy</td>
<td>85</td>
<td>70 (control) 63 (tocilizumab)</td>
<td>E</td>
<td>PaO2:FiO2 200-300 mmHg</td>
<td>Survival rate</td>
<td>8</td>
</tr>
<tr>
<td>Colaneri 2021</td>
<td>Retrospective case-control study</td>
<td>Italy</td>
<td>112</td>
<td>64 (control) 62 (tocilizumab)</td>
<td>A</td>
<td>CRP &gt;50 mg/L PaO2:FiO2 200-300 mmHg</td>
<td>ICU admission and seven-day mortality rate</td>
<td>8</td>
</tr>
<tr>
<td>De Rossi 2020</td>
<td>Retrospective cohort study</td>
<td>Italy</td>
<td>158</td>
<td>71 (control) 62.9 (tocilizumab)</td>
<td>B or D</td>
<td>CRP ≥ 100mg/L LDH &gt;220 U/L PaO2:FiO2 200-300 mmHg</td>
<td>Death and survival rate</td>
<td>7</td>
</tr>
<tr>
<td>Eimer 2021</td>
<td>Retrospective cohort study</td>
<td>Sweden</td>
<td>87</td>
<td>58 (control) 29 (tocilizumab)</td>
<td>A</td>
<td>CRP ≥ 100 mg/L</td>
<td>30-day all-cause mortality after admission to ICU</td>
<td>8</td>
</tr>
<tr>
<td>Gokhale 2020</td>
<td>Retrospective cohort study</td>
<td>India</td>
<td>161</td>
<td>55 (control) 52 (tocilizumab)</td>
<td>B</td>
<td>PaO2:FiO2 &lt; 200 mmHg</td>
<td>Death</td>
<td>8</td>
</tr>
<tr>
<td>Guaraldini 2020</td>
<td>Retrospective observational cohort study</td>
<td>Italy</td>
<td>544</td>
<td>69 (control) 64 (tocilizumab)</td>
<td>A</td>
<td>PaO2:FiO2 200-300 mmHg LDH &gt;220 U/L</td>
<td>Death or invasive mechanical ventilation</td>
<td>8</td>
</tr>
<tr>
<td>Study design</td>
<td>Country</td>
<td>Total patients</td>
<td>Mean/median age (years)</td>
<td>TCZ category</td>
<td>Baseline criteria for TCZ administration</td>
<td>Outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>----------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>------------------------------------------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retrospective multicenter cohort study</td>
<td>USA</td>
<td>485</td>
<td>63 (control) 58 (tocilizumab)</td>
<td>E</td>
<td>PaO2:FIO2 &lt; 200 mmHg</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retrospective observational cohort study</td>
<td>USA</td>
<td>547</td>
<td>69 (control) 62 (tocilizumab)</td>
<td>B</td>
<td>PaO2:FIO2 &lt; 200 mmHg</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retrospective cohort study</td>
<td>USA</td>
<td>51</td>
<td>70 (control) 62 (tocilizumab)</td>
<td>A</td>
<td>CRP &gt; 100 mg/L Fentanyl &gt; 900 ng/mL PaO2:FIO2 200-300 mmHg</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retrospective case-control study</td>
<td>France</td>
<td>45</td>
<td>71 (control) 77 (tocilizumab)</td>
<td>A</td>
<td>CRP &gt; 100 mg/L Fentanyl &gt; 900 ng/mL PaO2:FIO2 200-300 mmHg</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retrospective cohort study</td>
<td>Spain</td>
<td>138</td>
<td>68 (control) 62 (tocilizumab)</td>
<td>C</td>
<td>CRP &lt; 100 mg/L Fentanyl &lt; 900 ng/mL</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A prospective cohort study</td>
<td>Spain</td>
<td>196</td>
<td>73.5 (control) 64.5 (tocilizumab)</td>
<td>A</td>
<td>CRP &gt; 50 mg/L Fentanyl &lt; 900 ng/mL PaO2:FIO2 &gt; 200-300 mmHg</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retrospective observational single-center case-control study</td>
<td>Italy</td>
<td>111</td>
<td>56.2 (control) 62.4 (tocilizumab)</td>
<td>A</td>
<td>CRP &gt; 100 mg/L PaO2:FIO2 200-300 mmHg</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Article</td>
<td>Study design</td>
<td>Country</td>
<td>Total patients</td>
<td>Mean/median age (years)</td>
<td>TCZ category**</td>
<td>Baseline criteria for TCZ administration</td>
<td>Outcome</td>
<td>NOS</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>-------------------------</td>
<td>----------------</td>
<td>----------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-----</td>
</tr>
<tr>
<td>Ramiro 2020³³³</td>
<td>Retrospective case-control single-center study</td>
<td>Netherland</td>
<td>86</td>
<td>67 (control) 67 (tocilizumab)</td>
<td>A</td>
<td>CRP ≥ 100mg/L Ferritin &gt; 900ng/mL PaO2:FiO2 200-300 mmHg</td>
<td>Discharge from the hospital or improvement compared with baseline</td>
<td>9</td>
</tr>
<tr>
<td>Ramaswamy 2020³⁸</td>
<td>A case-control study</td>
<td>USA</td>
<td>86</td>
<td>21 (control) 65 (tocilizumab)</td>
<td>B</td>
<td>CRP &gt; 70mg/L PaO2:FiO2 200-300 mmHg</td>
<td>Mortality event</td>
<td>6</td>
</tr>
<tr>
<td>Rojas-Marté 2020⁶⁰</td>
<td>Retrospective single-center study</td>
<td>USA</td>
<td>193</td>
<td>62 (control) 59 (tocilizumab)</td>
<td>No detail was reported</td>
<td>CRP ≥ 100mg/L Ferritin &gt; 900ng/mL PaO2:FiO2 200-300 mmHg</td>
<td>Overall mortality rate</td>
<td>7</td>
</tr>
<tr>
<td>Rossotti 2020⁵¹</td>
<td>Retrospective case-control study</td>
<td>Italy</td>
<td>222</td>
<td>59 (control) 59 (tocilizumab)</td>
<td>A</td>
<td>PaO2:FiO2 200-300mmHg</td>
<td>Overall survival analysis</td>
<td>8</td>
</tr>
<tr>
<td>Salvatí 2020⁴²</td>
<td>Randomized controlled trial</td>
<td>USA</td>
<td>126</td>
<td>60 (control) 61.5 (tocilizumab)</td>
<td>A</td>
<td>CRP &gt; 100mg/dL PaO2:FiO2 200-300 mmHg Ferritin &lt; 900ng/L</td>
<td>Intensive care unit with invasive mechanical ventilation, death from all causes, or clinical aggravation</td>
<td>7</td>
</tr>
<tr>
<td>Somers 2020⁴³</td>
<td>Randomized controlled trial</td>
<td>USA</td>
<td>154</td>
<td>60 (control) 55 (tocilizumab)</td>
<td>A</td>
<td>CRP ≥ 100mg/L Ferritin &gt; 900ng/L PaO2:FiO2 &lt; 2000mmHg LDH &gt; 220U/L</td>
<td>Survival probability after intubation</td>
<td>6</td>
</tr>
</tbody>
</table>

**The dose and administration of tocilizumab are grouped into:**

- a. Category A: Intravenous Tocilizumab 8mg/kg bb up to 800 mg, added by a second dose after 12–24 hours
- b. Category B: Single dose intravenous Tocilizumab 400mg
- c. Category C: Single dose intravenous Tocilizumab 600mg
- d. Category D: 324 mg of Subcutaneous injections of tocilizumab
- e. Category E: not classified

TCZ, tocilizumab; NOS, Newcastle-Ottawa Scale; CRP, C-reactive protein; LDH, lactate dehydrogenase; ICU, intensive care unit.
Table 2. Outcome and laboratory marker Tocilizumab group and standard of care group.

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>N</th>
<th>Mode</th>
<th>Value</th>
<th>pE</th>
<th>pHet</th>
<th>P</th>
<th>RR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>SOC</td>
<td>TCZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>n</td>
<td>Total</td>
<td>n</td>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>26</td>
<td>Random</td>
<td>2475</td>
<td>61160</td>
<td>523</td>
<td>2112</td>
<td>0.2500</td>
<td>&lt;0.00001</td>
</tr>
<tr>
<td>Subgroup Analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP &gt;100 mg/L</td>
<td>13</td>
<td>Random</td>
<td>508</td>
<td>1114</td>
<td>234</td>
<td>894</td>
<td>0.1400</td>
<td>0.01</td>
</tr>
<tr>
<td>CRP &lt; 100 mg/L</td>
<td>7</td>
<td>Random</td>
<td>83</td>
<td>512</td>
<td>28</td>
<td>266</td>
<td>0.4500</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>P/F ratio 200–300 mmHg</td>
<td>15</td>
<td>Random</td>
<td>880</td>
<td>2137</td>
<td>296</td>
<td>1208</td>
<td>0.1300</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>P/F ratio &lt;200 mmHg</td>
<td>8</td>
<td>Fixed</td>
<td>1576</td>
<td>3829</td>
<td>220</td>
<td>722</td>
<td>0.6600</td>
<td>0.8400</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Length of stay (d)</td>
<td>11</td>
<td>Random</td>
<td>14.22±3.21</td>
<td>16.81±2.25</td>
<td>0.5300</td>
<td>&lt;0.0001</td>
<td>0.21</td>
<td>-2.05</td>
</tr>
<tr>
<td>Subgroup Analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP &gt;100 mg/L</td>
<td>8</td>
<td>Fixed</td>
<td>16.02±3.86</td>
<td>16.35±3.19</td>
<td>0.4800</td>
<td>0.7300</td>
<td>0.18</td>
<td>1.17</td>
</tr>
<tr>
<td>CRP &lt; 100 mg/L</td>
<td>3</td>
<td>Fixed</td>
<td>10.17±1.97</td>
<td>18.77±1.18</td>
<td>0.8500</td>
<td>0.8700</td>
<td>&lt;0.0001</td>
<td>-7.75</td>
</tr>
<tr>
<td>P/F ratio 200–300 mmHg</td>
<td>3</td>
<td>Fixed</td>
<td>14.28±2.73</td>
<td>14.28±1.53</td>
<td>0.8800</td>
<td>0.3700</td>
<td>0.30</td>
<td>1.15</td>
</tr>
<tr>
<td>P/F ratio &lt;200 mmHg</td>
<td>7</td>
<td>Random</td>
<td>15.36±5.73</td>
<td>18.74±2.23</td>
<td>0.7300</td>
<td>0.0007</td>
<td>0.33</td>
<td>-2.38</td>
</tr>
<tr>
<td>Days of death (d)</td>
<td>4</td>
<td>Random</td>
<td>13.32±3.33</td>
<td>6.89±6.52</td>
<td>0.1200</td>
<td>&lt;0.0001</td>
<td>0.04</td>
<td>6.03</td>
</tr>
</tbody>
</table>

Note, data were presents as mean ± SD or n [%], SOC, Standard of care; TCZ, tocilizumab; N, number of studies; CRP, C-reactive protein; RR, relative risk; MD, mean difference; pE, p Egger; PHet, p Heterogeneity; CI, confidence interval.

According to the Moreno-Perez study, candidates for tocilizumab treatment had poor prognostic factors or worsening disease. One of indication for worsening condition was CRP level >100 mg/L or P/F ratio <200 mmHg.34

Our subgroup analysis showed tocilizumab had a good result when CRP levels were ≥100 mg/L and P/F ratio was 200–300 mmHg or <200 mmHg. Administration of tocilizumab for CRP levels <100 mg/L did not reduce mortality and showed a longer length of stay in hospital.

There are various types of administration of tocilizumab treatment among studies. Tocilizumab can be administrated at a low dose (400 mg or 4 mg/kg) or high dose (800 mg or 8 mg/kg), as a single-dose and then continue with the second dose if clinical condition worsens in 24 hours (maximum 800 mg per dose), intravenously or subcutaneously.

Strengths and limitations of the analysis
Meta-analysis on this topic has not been previously conducted; only mortality events and ICU admissions have been reported by previous studies.6–11,13 In our study, we evaluate all-cause mortality events, length of stay in hospital, and days until death (time to death after first intervention) and carry out subgroup analysis of baseline criteria for administration of tocilizumab treatment. This study has a larger sample size; 2112 patients in the tocilizumab group and 6160 patients in the SOC group.

The limitations of this study are that we didn’t perform subgroup analysis outcomes according to the dosage and route of administration tocilizumab and didn’t analyze secondary outcomes after tocilizumab treatment like bacterial or fungal infections, thrombotic events, major bleeding, or requirement of invasive mechanical ventilation requirement. The results of our study should be used carefully because most studies included were retrospective and only two were randomized clinical trials, since it has been difficult to perform randomized trial during this pandemic. A meta-analysis of more clinical trial data will provide a more precise result for tocilizumab treatment in severe and critically ill COVID-19 patients.

Conclusion
Our study provides meaningful data regarding the effect of tocilizumab in severe and critically ill confirmed COVID-19
### Study or Subgroup

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>SOC Events</th>
<th>SOC Total</th>
<th>TCZ Events</th>
<th>TCZ Total</th>
<th>Weight</th>
<th>M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albertini 2020</td>
<td>0</td>
<td>22</td>
<td>1</td>
<td>22</td>
<td>0.3%</td>
<td>0.33 [0.01, 7.76]</td>
<td></td>
</tr>
<tr>
<td>Biran 2020</td>
<td>256</td>
<td>420</td>
<td>102</td>
<td>210</td>
<td>8.3%</td>
<td>1.25 [1.07, 1.47]</td>
<td></td>
</tr>
<tr>
<td>Campochiaro 2020</td>
<td>11</td>
<td>33</td>
<td>5</td>
<td>32</td>
<td>2.8%</td>
<td>2.13 [0.83, 5.45]</td>
<td></td>
</tr>
<tr>
<td>Canziani 2020</td>
<td>36</td>
<td>64</td>
<td>24</td>
<td>64</td>
<td>6.5%</td>
<td>1.50 [1.02, 2.20]</td>
<td></td>
</tr>
<tr>
<td>Capra 2020</td>
<td>11</td>
<td>23</td>
<td>2</td>
<td>22</td>
<td>1.5%</td>
<td>14.83 [3.55, 61.87]</td>
<td></td>
</tr>
<tr>
<td>Colaneri 2020</td>
<td>19</td>
<td>91</td>
<td>5</td>
<td>21</td>
<td>3.1%</td>
<td>0.88 [0.37, 2.08]</td>
<td></td>
</tr>
<tr>
<td>De Rossi 2020</td>
<td>34</td>
<td>68</td>
<td>7</td>
<td>90</td>
<td>3.7%</td>
<td>6.43 [3.04, 13.61]</td>
<td></td>
</tr>
<tr>
<td>Eimer 2020</td>
<td>19</td>
<td>58</td>
<td>5</td>
<td>29</td>
<td>3.0%</td>
<td>1.90 [0.79, 4.57]</td>
<td></td>
</tr>
<tr>
<td>Gokhale 2020</td>
<td>61</td>
<td>91</td>
<td>33</td>
<td>70</td>
<td>7.3%</td>
<td>1.42 [1.07, 1.89]</td>
<td></td>
</tr>
<tr>
<td>Guaraldi 2020</td>
<td>73</td>
<td>365</td>
<td>13</td>
<td>179</td>
<td>5.0%</td>
<td>2.75 [1.57, 4.83]</td>
<td></td>
</tr>
<tr>
<td>Gupta 2020</td>
<td>1419</td>
<td>3492</td>
<td>125</td>
<td>433</td>
<td>8.3%</td>
<td>1.41 [1.21, 1.64]</td>
<td></td>
</tr>
<tr>
<td>Ip 2020</td>
<td>231</td>
<td>413</td>
<td>62</td>
<td>134</td>
<td>8.0%</td>
<td>1.21 [0.99, 1.48]</td>
<td></td>
</tr>
<tr>
<td>Kewen 2020</td>
<td>2</td>
<td>23</td>
<td>3</td>
<td>28</td>
<td>1.1%</td>
<td>0.81 [0.15, 4.45]</td>
<td></td>
</tr>
<tr>
<td>Klopfenstein 2020</td>
<td>12</td>
<td>25</td>
<td>5</td>
<td>20</td>
<td>3.1%</td>
<td>1.92 [0.81, 4.55]</td>
<td></td>
</tr>
<tr>
<td>Masia 2020</td>
<td>8</td>
<td>62</td>
<td>2</td>
<td>76</td>
<td>1.3%</td>
<td>4.90 [1.08, 22.26]</td>
<td></td>
</tr>
<tr>
<td>Mikulska 2020</td>
<td>45</td>
<td>66</td>
<td>4</td>
<td>29</td>
<td>2.8%</td>
<td>4.94 [1.96, 12.46]</td>
<td></td>
</tr>
<tr>
<td>Moreno-Pérez 2020</td>
<td>3</td>
<td>159</td>
<td>10</td>
<td>77</td>
<td>1.8%</td>
<td>0.15 [0.04, 0.51]</td>
<td></td>
</tr>
<tr>
<td>Patel 2020</td>
<td>11</td>
<td>41</td>
<td>11</td>
<td>42</td>
<td>3.9%</td>
<td>1.02 [0.50, 2.10]</td>
<td></td>
</tr>
<tr>
<td>Potere 2020</td>
<td>11</td>
<td>40</td>
<td>2</td>
<td>40</td>
<td>1.4%</td>
<td>5.50 [1.30, 23.26]</td>
<td></td>
</tr>
<tr>
<td>Quattrocchio 2020</td>
<td>0</td>
<td>69</td>
<td>4</td>
<td>42</td>
<td>0.4%</td>
<td>0.07 [0.00, 1.24]</td>
<td></td>
</tr>
<tr>
<td>Ramaswamy 2020</td>
<td>8</td>
<td>65</td>
<td>3</td>
<td>21</td>
<td>1.9%</td>
<td>0.86 [0.25, 2.95]</td>
<td></td>
</tr>
<tr>
<td>Ramiro 2020</td>
<td>33</td>
<td>86</td>
<td>10</td>
<td>83</td>
<td>4.4%</td>
<td>3.18 [1.68, 6.04]</td>
<td></td>
</tr>
<tr>
<td>Rojas-Martí 2020</td>
<td>55</td>
<td>97</td>
<td>43</td>
<td>96</td>
<td>7.4%</td>
<td>1.27 [0.95, 1.68]</td>
<td></td>
</tr>
<tr>
<td>Rosotti 2020</td>
<td>89</td>
<td>148</td>
<td>26</td>
<td>74</td>
<td>6.9%</td>
<td>1.71 [1.22, 2.40]</td>
<td></td>
</tr>
<tr>
<td>Salvanini 2020</td>
<td>1</td>
<td>63</td>
<td>2</td>
<td>60</td>
<td>0.6%</td>
<td>0.48 [0.04, 5.12]</td>
<td></td>
</tr>
<tr>
<td>Somers 2020</td>
<td>27</td>
<td>76</td>
<td>14</td>
<td>78</td>
<td>5.0%</td>
<td>1.98 [1.13, 3.48]</td>
<td></td>
</tr>
</tbody>
</table>

Total (95% CI): 6160 / 2112 = 100.0% 1.65 [1.37, 2.00]

Total events: 2475 / 523 = 100.0%

Heterogeneity: Tau² = 0.11; Chisq = 83.22, df = 25 (P < 0.00001); I² = 70%

Test for overall effect: Z = 5.20 (P < 0.00001)

---

### Study or Subgroup

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>SOC Events</th>
<th>SOC Total</th>
<th>TCZ Events</th>
<th>TCZ Total</th>
<th>Weight</th>
<th>M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albertini 2020</td>
<td>0</td>
<td>20</td>
<td>1</td>
<td>22</td>
<td>0.7%</td>
<td>0.37 [0.02, 8.48]</td>
<td></td>
</tr>
<tr>
<td>Biran 2020</td>
<td>256</td>
<td>420</td>
<td>102</td>
<td>210</td>
<td>15.3%</td>
<td>1.25 [1.07, 1.47]</td>
<td></td>
</tr>
<tr>
<td>Campochiaro 2020</td>
<td>11</td>
<td>33</td>
<td>5</td>
<td>32</td>
<td>5.6%</td>
<td>2.13 [0.83, 5.45]</td>
<td></td>
</tr>
<tr>
<td>Canziani 2020</td>
<td>36</td>
<td>64</td>
<td>24</td>
<td>64</td>
<td>12.3%</td>
<td>1.50 [1.02, 2.20]</td>
<td></td>
</tr>
<tr>
<td>De Rossi 2020</td>
<td>34</td>
<td>68</td>
<td>7</td>
<td>90</td>
<td>7.4%</td>
<td>6.43 [3.04, 13.61]</td>
<td></td>
</tr>
<tr>
<td>Eimer 2020</td>
<td>19</td>
<td>58</td>
<td>5</td>
<td>29</td>
<td>6.1%</td>
<td>1.90 [0.79, 4.57]</td>
<td></td>
</tr>
<tr>
<td>Kewan 2020</td>
<td>2</td>
<td>23</td>
<td>3</td>
<td>28</td>
<td>2.3%</td>
<td>0.81 [0.15, 4.45]</td>
<td></td>
</tr>
<tr>
<td>Klopfenstein 2020</td>
<td>12</td>
<td>25</td>
<td>5</td>
<td>20</td>
<td>6.3%</td>
<td>1.92 [0.81, 4.55]</td>
<td></td>
</tr>
<tr>
<td>Patel 2020</td>
<td>11</td>
<td>41</td>
<td>11</td>
<td>42</td>
<td>7.7%</td>
<td>1.02 [0.50, 2.10]</td>
<td></td>
</tr>
<tr>
<td>Potere 2020</td>
<td>11</td>
<td>40</td>
<td>2</td>
<td>40</td>
<td>3.0%</td>
<td>5.50 [1.30, 23.25]</td>
<td></td>
</tr>
<tr>
<td>Ramiro 2020</td>
<td>33</td>
<td>86</td>
<td>10</td>
<td>83</td>
<td>8.6%</td>
<td>3.18 [1.68, 6.04]</td>
<td></td>
</tr>
<tr>
<td>Rojas-Martí 2020</td>
<td>55</td>
<td>97</td>
<td>43</td>
<td>96</td>
<td>13.8%</td>
<td>1.27 [0.95, 1.68]</td>
<td></td>
</tr>
<tr>
<td>Salvanini 2020</td>
<td>1</td>
<td>63</td>
<td>2</td>
<td>60</td>
<td>1.2%</td>
<td>0.48 [0.04, 5.12]</td>
<td></td>
</tr>
<tr>
<td>Somers 2020</td>
<td>27</td>
<td>76</td>
<td>14</td>
<td>78</td>
<td>9.6%</td>
<td>1.98 [1.13, 3.48]</td>
<td></td>
</tr>
</tbody>
</table>

Total (95% CI): 1114 / 894 = 100.0% 1.78 [1.35, 2.34]

Total events: 508 / 234 = 100.0%

Heterogeneity: Tau² = 0.12; Chisq = 35.88, df = 13 (P = 0.0006); I² = 64%

Test for overall effect: Z = 4.08 (P < 0.0001)
patients. Tocilizumab is a treatment option for severe and critically ill COVID-19 patients and it appears to reduce mortality events, especially when CRP level >100 mg/L, P/F ratio 200–300 mmHg, and P/F ratio <200 mmHg. However, tocilizumab should be used cautiously according to proper selection criteria to achieve optimal results and its use should be tailored
according to the eligibility of the patients. Further studies are still required, especially regarding optimal dosage and administration route of tocilizumab in COVID-19 patients.

**Data availability**

*Underlying data*

Figshare: Data systematic review and meta-analysis optimal use tocilizumab.zip. [https://doi.org/10.6084/m9.figshare.13655894.v1](https://doi.org/10.6084/m9.figshare.13655894.v1).

This project contains the following underlying data:

- TCZ_for_COVID-19.csv9

**Extended data**

Figshare: Data systematic review and meta-analysis optimal use tocilizumab.zip. [https://doi.org/10.6084/m9.figshare.13655894.v1](https://doi.org/10.6084/m9.figshare.13655894.v1).

This project contains the following extended data:

- PubMed and Cochrane search strategies (in JPG format)

**Reporting guidelines**


Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

**Acknowledgments**

We are here to thank Prof. Dr. dr. Nasronudin, Sp. PD K-PTI for supporting us in completing this study.

---

**References**


Zhongheng Zhang
Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang, China

This meta-analysis can provide updated evidence for an important clinical question; However, I have several comments:

1. The authors combined evidence from RCT and observational studies, which is not appropriate; the authors need to at least perform subgroup (sensitivity) analysis by restricting only high-quality trials.

2. Bayesian meta-analysis may be appropriate for down-weighing observational studies.

3. Most studies are small in sample size; the limitation of small study effect should be addressed and discussed; this effect has been well characterized in literature (Zhang et al., 2013).

4. Many observational studies may include adjusted effect size, try to combine this adjusted OR (RR) and to see whether this will change the current conclusion.

5. Many interventional meta-analysis on COVID-19 have been published in the literature (Kim et al., 2020; Aziz et al., 2021; Zhao et al., 2020 and Kotak et al., 2020); the authors need to clarify how their study can add to the existing literature.

References


**Are the rationale for, and objectives of, the Systematic Review clearly stated?**
Yes

**Are sufficient details of the methods and analysis provided to allow replication by others?**
Yes

**Is the statistical analysis and its interpretation appropriate?**
Partly

**Are the conclusions drawn adequately supported by the results presented in the review?**
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** critical care medicine

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 12 Mar 2021

**Satriyo Dwi Suryantoro,** Faculty of Medicine, Airlangga University, Surabaya, Indonesia

We would like to firstly express our gratitude for having our manuscript reviewed thoroughly.

Best regards,

Research team.

**Competing Interests:** We have no conflict of interest

Reviewer Report 02 March 2021

https://doi.org/10.5256/f1000research.48118.r79722

© 2021 Wiyono W. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Wiwien Heru Wiyono
Department of Pulmonology and Respiratory Medicine, Universitas Indonesia, Jakarta, Indonesia

1) Data extraction and quality assessment:
Two independent investigators conducted the study assessment (BAM and CW). Two authors (BAM and EA) extracted necessary data.
I think it is not necessary to inform that one acts as an independent investigator, while he is also a member of the authors who extracted the data. Its independence is questionable.

2) Conclusion:
Tocilizumab is a treatment option for severe and critically ill COVID-19 patients and it appears to reduce mortality events, especially when CRP level >100 mg/L, P/F ratio 200–300 mmHg, and P/F ratio < 200 mmHg.

1. The authors did not explain in the discussion that P/F ratio 200-300 mmHg and P/F ratio < 200 mmHg is actually different in mode.

2. When the mode of both variables is ignored, why not just conclude: when P/F ratio < 300 mm Hg.

3. Clinicians need clear conclusions, the authors' conclusions about P/F ratio 200-300 mmHg and P/F ratio < 200mm Hg are confusing.

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Yes

Are the conclusions drawn adequately supported by the results presented in the review?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical Pulmonology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Satriyo Dwi Suryantoro, Faculty of Medicine, Airlangga University, Surabaya, Indonesia

Dear Prof. Wiwien,
1) Thank you for the helpful and considerate advices.

2) To all intents and purposes, in this research we didn't particularly examine and conclude the effect of TCZ on P/F ratio less than 300, yet we figured out significantly good impact/effect of TCZ on patients with mild ARDS (P/F ratio 200-300 mmHg), as we have mentioned on page 9 of the manuscript.

**Competing Interests:** There is no financial competing interest. We hope to benefit as a result of our submission for further treatment COVID-19 using Tocilizumab.

---

**Reviewer Report 05 February 2021**

https://doi.org/10.5256/f1000research.48118.r78921

© 2021 Cosmi L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

---

**Lorenzo Cosmi**

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

The manuscript “Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis”, is an exhaustive meta-analysis on studies that have evaluated the efficacy of treatment with tocilizumab in COVID-19. The meta-analysis is well performed, and the results are convincing and in line with the real life evidences, which suggest an efficacy of such a treatment in selected patients. The authors correctly underline that the treatment works in patients with high inflammatory status and with impairment of respiratory function (P/F ratio below than 300 mm Hg). The concept that tocilizumab improves the prognosis of severe COVID-19 patients, reducing hyper inflammation that contributes to vascular pulmonary damage is an important message for the scientific community.

I have no particular concerns on this manuscript. I only suggest to quote in the introduction also a recent paper that focuses on the ability of tocilizumab to improve the lung perfusion in these patients (Salvati et al., 2020).

**References**


**Are the rationale for, and objectives of, the Systematic Review clearly stated?**

Yes

**Are sufficient details of the methods and analysis provided to allow replication by others?**
Yes

Is the statistical analysis and its interpretation appropriate?
Yes

Are the conclusions drawn adequately supported by the results presented in the review?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** COVID-19

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com